tradingkey.logo

Xencor Inc

XNCR
15.450USD
-0.020-0.13%
Close 12/24, 13:00ETQuotes delayed by 15 min
1.10BMarket Cap
LossP/E TTM

Xencor Inc

15.450
-0.020-0.13%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Xencor Inc

Currency: USD Updated: 2025-12-24

Key Insights

Xencor Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 52/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.00.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Xencor Inc's Score

Industry at a Glance

Industry Ranking
52 / 404
Overall Ranking
135 / 4562
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 14 analysts
Buy
Current Rating
28.000
Target Price
+58.37%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Xencor Inc Highlights

StrengthsRisks
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 110.49M.
Fairly Valued
The company’s latest PE is -8.96, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.43M shares, decreasing 6.98% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 192.79K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-24

The current financial score of Xencor Inc is 7.70, ranking 90/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 21.00M, representing a year-over-year increase of 96.07%, while its net profit experienced a year-over-year increase of 86.65%.

Score

Industry at a Glance

Previous score
7.70
Change
0

Financials

5.33

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

5.99

Shareholder Returns

7.19

Xencor Inc's Company Valuation

Currency: USD Updated: 2025-12-24

The current valuation score of Xencor Inc is 7.12, ranking 178/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.96, which is -72.33% below the recent high of -2.48 and -345.90% above the recent low of -39.94.

Score

Industry at a Glance

Previous score
7.12
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 52/404
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-24

The current earnings forecast score of Xencor Inc is 8.43, ranking 128/404 in the Biotechnology & Medical Research industry. The average price target for Xencor Inc is 27.00, with a high of 42.00 and a low of 17.00.

Score

Industry at a Glance

Previous score
8.43
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts
Buy
Current Rating
28.000
Target Price
+58.37%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

534
Total
6
Median
6
Average
Company name
Ratings
Analysts
Xencor Inc
XNCR
14
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-24

The current price momentum score of Xencor Inc is 6.64, ranking 228/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 17.77 and the support level at 14.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.43
Change
0.21

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.578
Neutral
RSI(14)
45.257
Neutral
STOCH(KDJ)(9,3,3)
17.746
Neutral
ATR(14)
0.850
Low Volatility
CCI(14)
-118.472
Sell
Williams %R
87.097
Oversold
TRIX(12,20)
0.095
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
15.626
Sell
MA10
16.085
Sell
MA20
16.623
Sell
MA50
15.428
Buy
MA100
12.412
Buy
MA200
10.904
Buy

Institutional Confidence

Currency: USD Updated: 2025-12-24

The current institutional shareholding score of Xencor Inc is 10.00, ranking 1/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 112.65%, representing a quarter-over-quarter decrease of 1.63%. The largest institutional shareholder is PRIMECAP Management, holding a total of 10.68M shares, representing 14.95% of shares outstanding, with 9.00% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
PRIMECAP Management Company
Star Investors
10.53M
+7.85%
BlackRock Institutional Trust Company, N.A.
10.67M
-0.64%
The Vanguard Group, Inc.
Star Investors
8.61M
+9.21%
RTW Investments L.P.
2.40M
--
EcoR1 Capital, LLC
6.14M
--
BVF Partners L.P.
2.74M
--
State Street Investment Management (US)
3.82M
+3.63%
TCG Crossover Management, LLC
2.45M
--
Geode Capital Management, L.L.C.
1.70M
+1.75%
Dimensional Fund Advisors, L.P.
1.78M
+2.49%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-24

The current risk assessment score of Xencor Inc is 4.44, ranking 93/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.44
Change
0
Beta vs S&P 500 index
0.97
VaR
+4.72%
240-Day Maximum Drawdown
+66.13%
240-Day Volatility
+71.36%

Return

Best Daily Return
60 days
+13.44%
120 days
+13.44%
5 years
+22.93%
Worst Daily Return
60 days
-10.96%
120 days
-10.96%
5 years
-21.08%
Sharpe Ratio
60 days
+2.04
120 days
+2.17
5 years
-0.18

Risk Assessment

Maximum Drawdown
240 days
+66.13%
3 years
+81.06%
5 years
+85.01%
Return-to-Drawdown Ratio
240 days
-0.38
3 years
-0.24
5 years
-0.16
Skewness
240 days
+0.06
3 years
+0.45
5 years
+0.41

Volatility

Realised Volatility
240 days
+71.36%
5 years
+53.77%
Standardised True Range
240 days
+4.88%
5 years
+7.15%
Downside Risk-Adjusted Return
120 days
+427.50%
240 days
+427.50%
Maximum Daily Upside Volatility
60 days
+56.81%
Maximum Daily Downside Volatility
60 days
+53.13%

Liquidity

Average Turnover Rate
60 days
+0.99%
120 days
+1.19%
5 years
--
Turnover Deviation
20 days
+5.46%
60 days
-0.02%
120 days
+20.07%

Peer Comparison

Biotechnology & Medical Research
Xencor Inc
Xencor Inc
XNCR
7.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Xencor Inc?

The TradingKey Stock Score provides a comprehensive assessment of Xencor Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Xencor Inc’s performance and outlook.

How do we generate the financial health score of Xencor Inc?

To generate the financial health score of Xencor Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Xencor Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Xencor Inc.

How do we generate the company valuation score of Xencor Inc?

To generate the company valuation score of Xencor Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Xencor Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Xencor Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Xencor Inc.

How do we generate the earnings forecast score of Xencor Inc?

To calculate the earnings forecast score of Xencor Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Xencor Inc’s future.

How do we generate the price momentum score of Xencor Inc?

When generating the price momentum score for Xencor Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Xencor Inc’s prices. A higher score indicates a more stable short-term price trend for Xencor Inc.

How do we generate the institutional confidence score of Xencor Inc?

To generate the institutional confidence score of Xencor Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Xencor Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Xencor Inc.

How do we generate the risk management score of Xencor Inc?

To assess the risk management score of Xencor Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Xencor Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Xencor Inc.
KeyAI